Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
The diagnosis of atypical KD should be considered in children with prolonged unexplained fever, less than 4 of the AHA criteria, compatible laboratory findings, or concerning echocardiographic findings (such as coronary artery aneurysm or reduced EF) (Figure 4)
Gray area exists but clinics operating this way haven't faced legal action
Are you under more stress than usual
And that's about the best feeling because they they know that you've lost some weight, but they don't even know what to say
